Evidence network for deaths_(OS)

1KEYNOTE-361 (PC vs C), 20211IMvigor-130 (At-arm A vs Pl-arm C), 20202DANUBE (D vs C - PDL1>25%), 2020 DANUBE (D vs C - all population), 20201IMvigor-130 (At-arm B vs Ch-armC), 20202DANUBE (DT vs C - all population), 2020 DANUBE (DT vs C - PDL1>25%), 20201KEYNOTE-361 (P vs C), 2021gemcitabine plus platinplacebo plus SoCStandard of Care (SoC)pembrolizumab plus SoCatezolizumab plus SoCdurvalumab aloneatezolizumab alonedurvalumab plus tremelimumabpembrolizumab alonedirect evidencenetwork meta-analysis
T vs. C gemcitabine plus platinplacebo plus SoCStandard of Care (SoC)pembrolizumab plus SoCatezolizumab plus SoCdurvalumab aloneatezolizumab alonedurvalumab plus tremelimumabpembrolizumab alone
gemcitabine plus platin---NANANANANANANANA
placebo plus SoCNA---NANANANANANANA
Standard of Care (SoC)NANA---NANANANANANA
pembrolizumab plus SoCNANANA---NANANANANA
atezolizumab plus SoCNANANANA---NANANANA
durvalumab aloneNANANANANA---NANANA
atezolizumab aloneNANANANANANA---NANA
durvalumab plus tremelimumabNANANANANANANA---NA
pembrolizumab aloneNANANANANANANANA---

pathologies: 288,153,157 - treatments: 359,575,577,576,869 result logic